Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (lDet) and insulin aspart (IAsp) from the PREFER treat-to-target study

被引：0
|
作者：
Liebl, A.
Compion, G.
Prager, R.
Binz, K.
Kaiser, M.
Gallwitz, B.
机构：
[1] Ctr Diabet & Metab, Bad Heilbrunn, Germany
[2] Novo Nordisk Ltd, Crawley, England
[3] Inst Metab Dis & Nutr, Med Abt Stoffwechselerkrankungen & Nephrol, Vienna, Austria
[4] Triemli City Hosp, Dept Endocrinol & Diabet, Zurich, Switzerland
[5] Novo Nordisk Pharma GmbH, Dept Diabet, Mainz, Germany
[6] Univ Tubingen, Med Klin 4, Tubingen, Germany
来源：
DIABETIC MEDICINE | 2007年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [31] Effect of biphasic insulin aspart 30/70 (BIAsp30) in combination with metformin on glycaemic control in subjects with type 2 diabetes not optimally controlled on oral antidiabetic agents
    Naiker, P.
    Makan, H. A.
    Omar, M. A. K.
    Kedijang, T.
    Kong, L. L. L.
    [J]. DIABETOLOGIA, 2006, 49 : 599 - 600
  • [32] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    [J]. DIABETOLOGIA, 2011, 54 : S423 - S423
  • [33] Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
    Jihad Haddad
    Mohsen Khoshniatnikoo
    Youcef Benabbas
    Serdar Guler
    Vinay Prusty
    Pradana Soewondo
    [J]. Diabetes Therapy, 2013, 4 : 309 - 319
  • [34] Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
    Haddad, Jihad
    Khoshniatnikoo, Mohsen
    Benabbas, Youcef
    Guler, Serdar
    Prusty, Vinay
    Soewondo, Pradana
    [J]. DIABETES THERAPY, 2013, 4 (02) : 309 - 319
  • [35] Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: A multicenter, observational, primary care study conducted in Finland
    Makela, Jyrki K.
    Schmuser, Christine
    Askonen, Kari
    Saukkonen, Tero
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 95 (01) : 10 - 18
  • [36] Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
    McCrimmon, Rory J.
    Home, Philip
    Cheng, Alice
    Giorgino, Francesco
    Fonseca, Vivian
    Souhami, Elisabeth
    Alvarez, Agustina
    Picard, Pascaline
    Rosenstock, Julio
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (12): : 2391 - 2399
  • [37] Patient treatment satisfaction before starting biphasic insulin aspart (BIAsp 30):: EMPROVE™ study data from China, Japan and Poland
    Gumprecht, Janusz
    Wenying, Yang
    Valensi, Paul
    Christensen, Torsten
    Borzi, Vito
    [J]. DIABETES, 2007, 56 : A506 - A506
  • [38] Biphasic insulin aspart 30: A guide to its use in diabetes mellitus
    Hines M.
    Lyseng-Williamson K.W.
    [J]. Drugs & Therapy Perspectives, 2013, 29 (5) : 135 - 140
  • [39] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
  • [40] Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus
    Velasquez-Mieyer, Pedro A.
    Neira, Claudia P.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (13) : 2377 - 2382
12345